- Lexaria Bioscience Corp LEXX LEXXW announced additional findings from last year's human clinical Study HYPER-H21-4 demonstrating significant reductions in several pro-inflammatory biomarkers known to be linked to cardiovascular disease (CVD).
- After five weeks of treatment with the patented DehydraTECH-processed cannabidiol (CBD) capsule formulation, blood-plasma levels of interleukin (IL) 8, 10, and 18 were reduced by ~19%, ~27%, and ~43%, respectively.
- Also Read: Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH.
- Those receiving five weeks of placebo experienced no significant changes in their IL levels.
- The differences evidenced relative to baseline and/or placebo with pro-inflammatory biomarkers IL 8, 10, and 18 were statistically significant.
- IL-10 levels are known to increase along with the reduction of kidney function; higher serum IL-10 levels have been associated with the risk of cardiovascular events during follow-up.
- Similarly, IL-18 is an independent predictor of cardiovascular events in patients with metabolic syndrome. In large population-based studies, circulating IL-18 is prospectively and independently associated with CVD risk.
- Lexaria previously announced that the Study's primary efficacy and safety objectives were successfully achieved, with resting blood pressure significantly reduced in hypertensive patients and sustained over the 5 weeks of dosing, with zero serious adverse events reported throughout the Study.
- Price Action: LEXX shares are up 6.60% at $0.73 on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
